EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, TransMedics Group's Enterprise Value is €2,435.5 Mil.
TransMedics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €130.1 Mil. Therefore, TransMedics Group's EV-to-FCF for today is 18.72.
The historical rank and industry rank for TransMedics Group's EV-to-FCF or its related term are showing as below:
HAM:8T8'
s EV-to-FCF Range Over the Past 10 Years
Min: -93.49 Med: -17.14 Max: 308.79
Current: 18.28
During the past 10 years, the highest EV-to-FCF of TransMedics Group was 308.79. The lowest was -93.49. And the median was -17.14.
HAM:8T8's EV-to-FCF is ranked better than 61.72% of 418
companies
in the Medical Devices & Instruments industry
Industry Median: 22.765
vs HAM:8T8: 18.28
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TransMedics Group's PE Ratio (TTM) for today is calculated as:
TransMedics Group's share price for today is €60.02.
TransMedics Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €3.770.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
TransMedics Group EV-to-FCF Related Terms
TransMedics Group EV-to-FCF Historical Data
* Premium members only.
The historical data trend for TransMedics Group's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TransMedics Group's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where TransMedics Group's EV-to-FCF falls into.
TransMedics Group's current Enterprise Value is €2,435.5 Mil.
TransMedics Group's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €130.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group (HAM:8T8) has a EV-to-FCF of 18.72 as of Jun. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TransMedics Group and its competitors. According to the industry distribution chart, TransMedics Group ranks #160 out of 418 companies in the Medical Devices & Instruments industry, placing it in the top 38.3%.
Is TransMedics Group's EV-to-FCF too high?
TransMedics Group's current EV-to-FCF is 18.72. The Medical Devices & Instruments industry median EV-to-FCF is 22.77. TransMedics Group's value of 18.72 is 17.8% below this industry median. Based on the distribution chart, TransMedics Group ranks #160 out of 418 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, TransMedics Group has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's EV-to-FCF compare to AXGN and BFLY?
According to the Medical Devices & Instruments industry distribution chart, TransMedics Group ranks #160 out of 418 companies for EV-to-FCF. This puts TransMedics Group in the upper half of its industry. The industry median EV-to-FCF is 22.77. TransMedics Group's value of 18.72 is 17.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 22.77, based on 418 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TransMedics Group's current EV-to-FCF of 18.72 is 17.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on TransMedics Group and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 22.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TransMedics Group's current EV-to-FCF is 18.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
TransMedics Group (HAM:8T8) has a current EV-to-FCF of 18.72. The stock's GF Value™ is €162.08, compared to a current price of €60.02 — trading 63% below its estimated fair value. The current EV-to-FCF is 18.72 and 17.8% below the Medical Devices & Instruments industry median of 22.77. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For TransMedics Group (HAM:8T8), the current EV-to-FCF is 18.72 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (HAM:8T8) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of €60.02 is trading 63% below its estimated GF Value™ of €162.08.
Key valuation signals for HAM:8T8:
EV-to-FCF: 18.72
GF Value™: €162.08 vs. price of €60.02 (63% below fair value)
Industry Position: 17.8% below the Medical Devices & Instruments median (#160 of 418)
No single metric tells the full story. See the HAM:8T8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for HAM:8T8
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:8T8 has been successfully added to your 
